Nucleome Therapeutics Appoints Dr. Michelle Morrow as Chief Scientific Officer
Nucleome Therapeutics announces Dr. Michelle Morrow as CSO effective February 23, 2026, bringing two decades of drug discovery experience as the company advances lead candidate NTP464 toward IND enabling studies.